ClinicalTrials.gg
CompletedNCT00849862Updated Sep 11, 2009Results posted

Levetiracetam 750 mg Tablets Under Fasting Conditions

A Phase 1 interventional study of Levetiracetam and Keppra® in Healthy, sponsored by Teva Pharmaceuticals USA. Completed at 1 site in Canada. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-09-11.

Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The objective of this study is to compare the rate and extent of absorption of a test formulation of Levetiracetam and the reference Keppra® administered as a 1 x 750 mg tablet under fasting conditions.

Read the detailed description

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA bioequivalence statistical methods

02

Conditions studied

  • Healthy

Keywords

  • Bioequivalence
  • Healthy Subjects
03

In context

Lead sponsor

Teva Pharmaceuticals USA is the lead sponsor of 176 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or Female, smoker or non-smoker, between the ages of 18 years and 55 years.
  • greater than or equal to 19.0 and less than 30.0 kg/m2.

Exclusion criteria

Exclusion Criteria

Subjects to whom any of the following applies will be excluded from the study:

  • illnesses or surgery within 4 weeks of the administration of study medication.
  • Any clinically significant abnormality or abnormal laboratory test results found during medical screening.
  • Any reason which, in the opinion of the medical subinvestigator, would prevent the subject from participating in the study.
  • Positive testing for , or at screening.
  • abnormalities (clinically significant) or vital sign abnormalities (systolic blood pressure lower than 90 or over 140 mmHg, or diastolic blood pressure lower than 50 or over 90; or heart rate less than 50 bpm or over 100 bpm) at screening.
  • History of significant alcohol abuse or drug abuse within one year prior to the screening visit.
  • Regular use of alcohol within six months prior to the screening visit (more than fourteen units of alcohol per week [1 Unit = 150 mL of wine, 360 mL of beer or 45 mL of 40% alcohol]), or positive alcohol breath test at screening.
  • Use of soft drugs (such as marijuana) within 3 months of the screening visit or hard drugs (such as cocaine, phencyclidine (PCP) and crack) within 1 year of the screening visit or positive urine drug screen at screening.
  • History of allergic reactions to heparin, levetiracetam, or other related drugs.
  • Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of inducers: barbiturates, carbamazepine, phenytoin, , omeprazole; examples of inhibitors: antidepressants, cimetidine, diltiazem, macrolides, imidazoles, neuroleptics, verapamil, fluoroquinolones, antihistamines) within 30 days prior to the administration of the study medication.
  • Use of an drug or participation in an investigational study within 30 days prior to dosing.
  • Clinically significant history or presence of any gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowel diseases), unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting), liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism or excretion of the drug.
  • Any clinically significant history or presence of neurological, endocrinal, cardiovascular, pulmonary, hematologic, immunologic, psychiatric or metabolic disease.
  • Use of prescription medication within 14 days prior to administration of study medication or over-the-counter products) including natural food supplements, vitamins, garlic as a supplement) within 7 days prior to administration of study medication, except for topical products without systemic absorption.
  • Difficulty to swallow study medication.
  • Smoking more than 25 cigarettes per day.
  • Any food allergy, intolerance, restriction, or special diet, that, in the opinion of the Medical Sub-Investigator could contraindicate the subject's participation in this study.
  • A depot injection or an implant of an drug within 6 months prior to administration of study medication.
  • Donation of plasma (500 mL) within 30 days prior to drug administration. Donation or loss of whole blood (excluding the volume of blood that will be drawn during the screening procedures of this study) prior to administration of the study medication as follows:
  • 50 mL to 500 mL of whole blood within 30 days
  • more than 500 mL of whole blood within 56 days.+
  • Difficulty fasting or consuming the standard meals.
  • Intolerance to venipunctures.
  • Clinically significant history of renal, hepatic, or cardiovascular disease, tuberculosis, epilepsy, asthma, diabetes, psychosis or glaucoma will not be eligible for this study.
  • Positive urine pregnancy test at screening.
  • Breast feeding subjects.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Levetiracetam

    Levetiracetam 750 mg Tablet (test) dosed in first period followed by Keppra 750 mg Tablet (reference) dosed in second period

    Drug: Levetiracetam

  • Active comparator
    Keppra®

    Keppra® 750 mg Tablet (reference) dosed in first period followed by Levetiracetam 750 mg Tablet (test) dosed in second period

    Drug: Keppra®

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax - Maximum Observed Concentration

    Bioequivalence based on Cmax

    Time frame: Blood samples collected over 36 hour period

  2. AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)

    Bioequivalence based on AUC0-inf

    Time frame: Blood samples collected over 36 hour period

  3. AUC0-t - Area Under Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)

    Bioequivalence based on AUC0-t

    Time frame: Blood samples collected over 36 hour period

07

Results

Posted Aug 4, 2009

Participant flow

First Intervention
Participant flow — First Intervention
MilestoneLevetiracetam (Test) FirstKeppra® (Reference) First
Started1111
Completed1111
Not completed00
Washout: 7 Days
Participant flow — Washout: 7 Days
MilestoneLevetiracetam (Test) FirstKeppra® (Reference) First
Started1111
Completed1111
Not completed00
Second Intervention
Participant flow — Second Intervention
MilestoneLevetiracetam (Test) FirstKeppra® (Reference) First
Started1111
Completed1111
Not completed00

Outcome measures

PrimaryCmax - Maximum Observed Concentration

Bioequivalence based on Cmax

Time frame:
Blood samples collected over 36 hour period
Reported as:
Mean · mcg/mL
Cmax - Maximum Observed Concentration
mcg/mLLevetiracetamKeppra®
Cmax - Maximum Observed Concentration21.625 ± 5.69923.501 ± 6.247
Statistical analysis
  • Levetiracetam vs Keppra® · Geometric test/ref ratio x 100: 92.2 · 90% CI 85.0 to 100Bioequivalence is established when 90% Confidence Interval falls within 80-125.
PrimaryAUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)

Bioequivalence based on AUC0-inf

Time frame:
Blood samples collected over 36 hour period
Reported as:
Mean · mcg*h/mL
AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)
mcg*h/mLLevetiracetamKeppra®
AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)186.097 ± 35.240185.293 ± 29.845
Statistical analysis
  • Levetiracetam vs Keppra® · Geometric test/ref ratio x 100: 100 · 90% CI 96.3 to 104Bioequivalence is established when 90% Confidence Interval falls within 80-125.
PrimaryAUC0-t - Area Under Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)

Bioequivalence based on AUC0-t

Time frame:
Blood samples collected over 36 hour period
Reported as:
Mean · mcg*h/mL
AUC0-t - Area Under Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)
mcg*h/mLLevetiracetamKeppra®
AUC0-t - Area Under Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)173.932 ± 33.436174.275 ± 31.177
Statistical analysis
  • Levetiracetam vs Keppra® · Geometric test/ref ratio x 100: 99.6 · 90% CI 96.2 to 103Bioequivalence is established when 90% Confidence Interval falls within 80-125.

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Levetiracetam (Test) FirstKeppra® (Reference) FirstTotal
<=18 years000
Between 18 and 65 years111122
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Levetiracetam (Test) FirstKeppra® (Reference) FirstTotal
Female268
Male9514
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Levetiracetam (Test) FirstKeppra® (Reference) FirstTotal
Caucasian11920
American Hispanic022
Region of Enrollment
Region of Enrollment(participants)Levetiracetam (Test) FirstKeppra® (Reference) FirstTotal
Canada111122
08

Study locations

1 site
  • SFBC-Anapharm
    Sainte-Foy, Quebec G1V 2K8, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2005, a primary completion of Nov 2005 and a completion of Nov 2005. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2009, 3 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2009
First posted
Feb 24, 2009
Start
Oct 2005
Primary completionActual
Nov 2005
CompletionActual
Nov 2005
Results first posted
Aug 4, 2009
Last update
Sep 11, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00849862
First posted
Feb 24, 2009
Start date
Oct 2005
Primary completion
Nov 2005
Completion
Nov 2005
Results posted
Aug 4, 2009
Last update
Sep 11, 2009

Study contacts

Richard Larouche, MD
principal investigator · SFBC Anapharm

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion